PROVEXIS PLC Logo

PROVEXIS PLC

Develops & licenses Fruitflow®, a patented ingredient for heart health in food & supplements.

PXS | IL

Overview

Corporate Details

ISIN(s):
GB00B0923P27
LEI:
21380042E3Y3N9VZ6N48
Country:
United Kingdom
Address:
2 BLAGRAVE STREET, RG1 1AZ READING
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Provexis PLC is a life sciences company specializing in the development, licensing, and sale of scientifically-proven technologies for the functional food, medical food, and dietary supplement sectors. The company's core asset is Fruitflow®, a proprietary and patented natural ingredient clinically proven to support cardiovascular health. Provexis operates a dual business model, licensing Fruitflow® to international food and supplement companies for use in their products, while also marketing its own branded dietary supplements containing Fruitflow® and Omega-3 directly to consumers and through retail partners.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-30 08:00
Earnings Release
Final Results
English 388.4 KB
2025-09-30 09:40
Report Publication Announcement
Delay in publication of annual accounts
English 18.0 KB
2025-01-07 14:14
Related Party Transaction
Grant of Options and Warrants
English 32.6 KB
2024-12-31 14:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 13.8 KB
2024-12-31 10:59
Interim Report
Half-year Report
English 212.7 KB
2024-12-18 08:00
Major Shareholding Notification
Purchase of Fruitflow® II SD & royalty payment
English 18.8 KB
2024-10-25 16:47
Declaration of Voting Results & Voting Rights Announcements
Result of AGM
English 24.2 KB
2024-09-30 08:00
Earnings Release
Final Results
English 384.9 KB
2024-04-30 18:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 13.7 KB
2024-03-28 08:00
Share Issue/Capital Change
Issue of Equity - purchase of Fruitflow® II SD
English 18.8 KB
2023-12-29 13:48
Earnings Release
Half-year Report
English 198.4 KB
2023-10-26 14:51
Declaration of Voting Results & Voting Rights Announcements
Result of AGM
English 23.8 KB
2023-09-29 08:00
Earnings Release
Final Results
English 374.8 KB
2023-08-30 08:04
Regulatory News Service
BYHEALTH regulatory filing with Chinese SAMR
English 16.5 KB
2023-04-03 08:00
Capital/Financing Update
Capital structure and funding update
English 22.3 KB

Automate Your Workflow. Get a real-time feed of all PROVEXIS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PROVEXIS PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PROVEXIS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Medivir Logo
Clinical-stage pharma firm developing tumor-directed therapies for high-need cancer patients.
Sweden MVIR
Sweden MBOLIC
Milton Essex Spolka Akcyjna Logo
Develops AI-powered, non-invasive systems for allergy diagnostics & personalized medicine.
Poland MTN
Molecular Partners AG Logo
Pioneering DARPin protein drugs for complex diseases in oncology and virology.
Switzerland MOLN
MorphoSys AG Logo
Biopharma company creating antibody therapies for oncology, with a focus on blood cancers.
Germany MOR
Mycodern Spolka Akcyjna Logo Poland MCD
N4 PHARMA PLC Logo
Developing a nanoparticle delivery system for advanced gene and vaccine therapies.
United Kingdom N4P
NextGen Biomed Ltd. Logo
R&D of biotech medical devices for diabetes care and topical skin treatments.
Israel NXGN
Nicox S.A. Logo
Developing innovative ophthalmology drugs for glaucoma and ocular hypertension.
France COX
ONCIMMUNE HOLDINGS PLC Logo
Antibody biomarker discovery platform for pharma and biotech partners in oncology and autoimmune disease.
United Kingdom ONC

Talk to a Data Expert

Have a question? We'll get back to you promptly.